Vol. 2 No. 14: Immunomodulatory drugs: the foundation for treating hematological malignancies Amsterdam, 15 June 2006

Articles

• Introduction

  Meletios Dimopoulos

  https://doi.org/10.4081/hmr.v2i14.507

  Published: June 10, 2009

  134

  PDF: 101

  • PDF

• Improving treatment outcomes by understanding cytogenetics in myelodysplastic

  Aristotle Giagounidis

  https://doi.org/10.4081/hmr.v2i14.508

  Published: June 10, 2009

  162

  PDF: 323

  • PDF

• Transfusion independence and cytogenetic response in myelodysplastic syndromes. What this means for the patient

  Alan F. List

  https://doi.org/10.4081/hmr.v2i14.509

  Published: June 10, 2009

  175

  PDF: 515

  • PDF

• Prolonging time to progression and survival in relapsed/refractory multiple myeloma

  Pieter Sonneveld

  https://doi.org/10.4081/hmr.v2i14.510

  Published: June 10, 2009

  183

  PDF: 386

  • PDF

• Targeting the microenvironment: a new treatment paradigm for chronic lymphocytic leukaemia

  Asher Chanan-Khan

  https://doi.org/10.4081/hmr.v2i14.511

  Published: June 10, 2009

  162

  PDF: 420

  • PDF